Patents by Inventor Lambertus Benthem

Lambertus Benthem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same
    Publication number: 20230135552
    Abstract: The present invention relates to compounds that can act as inhibitors of ketohexokinase (KHK) and that can be useful in the treatment of diseases and/or disorders associated with KHK. In some embodiments, the present invention relates to compounds and compositions that inhibit KHK and methods for their preparation and use.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 4, 2023
    Applicant: Inorbit Therapeutics AB
    Inventors: Lambertus Benthem, Robert Judkins
  • FARNESOID X RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME
    Publication number: 20230096663
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 30, 2023
    Inventors: Robert Judkins, Lambertus Benthem, Rajiv Sharma
  • Compounds useful in modulating the farnesoid X receptor and methods of making and using the same
    Patent number: 11339153
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR such as bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, kidney disorders (including chronic kidney disease), hepatic and colon cancers, and other disorders. The compounds are in the class of sulfinic acid compounds and can be an enantiomer, stereoisomer, tautomer, solvate, hydrate, prodrug, metabolite, or pharmaceutically acceptable salt thereof. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: May 24, 2022
    Assignee: Inorbit Therapeutics AB
    Inventors: Rajiv Sharma, Lambertus Benthem, Robert Judkins
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20220098265
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: BALAJI AGORAM, Madeleine Antonsson, MARIA A. BEDNAREK, Nicole Burmeister, Lambertus Benthem, DAVID FAIRMAN, MARIA FRITSCH-FREDIN, Ronald JACKSON, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 11230584
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210309656
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Application
    Filed: August 6, 2019
    Publication date: October 7, 2021
    Inventors: Rajiv Sharma, Lambertus Benthem, Robert Judkins
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20200115431
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Inventors: Balaji AGORAM, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David FAIRMAN, Maria FRITSCH-FREDIN, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 10556939
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20170342121
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 9765130
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 19, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 Agonists For The Treatment Of Obesity
    Publication number: 20150307579
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 29, 2015
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe